Addressing guideline and policy changes during pragmatic clinical trials

Lesley H. Curtis, Laura M. Dember, Miguel A Vazquez, David Murray, Lynn DeBar, Karen L. Staman, Edward Septimus, Vincent Mor, Angelo Volandes, Barbara L. Wells, Susan S. Huang, Beverly B. Green, Gloria Coronado, Catherine M. Meyers, Leah Tuzzio, Adrian F. Hernandez, Jeremy Sugarman

Research output: Contribution to journalArticle

Abstract

While conducting a set of large-scale multi-site pragmatic clinical trials involving high-impact public health issues such as end-stage renal disease, opioid use, and colorectal cancer, there were substantial changes to both policies and guidelines relevant to the trials. These external changes gave rise to unexpected challenges for the trials, including decisions regarding how to respond to new clinical practice guidelines, increased difficulty in implementing trial interventions, achieving separation between treatment groups, and differential responses across sites. In this article, we describe these challenges and the approaches used to address them. When deliberating appropriate action in the face of external changes during a pragmatic clinical trial, we recommend considering the well-being of the participants, clinical equipoise, and the strength and quality of the evidence associated with the change; involving those charged with data and safety monitoring; and where possible, planning for potential external changes as the trial is being designed. Any solution must balance the primary obligation to protect the well-being of participants with the secondary obligation to protect the integrity of the trial in order to gain meaningful answers to important public health questions.

Original languageEnglish (US)
Pages (from-to)431-437
Number of pages7
JournalClinical trials (London, England)
Volume16
Issue number4
DOIs
StatePublished - Aug 1 2019

Fingerprint

Pragmatic Clinical Trials
Public Health
Guidelines
Practice Guidelines
Opioid Analgesics
Chronic Kidney Failure
Colorectal Neoplasms
Safety

Keywords

  • guideline changes
  • Pragmatic clinical trials
  • pragmatic research
  • public health

ASJC Scopus subject areas

  • Pharmacology

Cite this

Curtis, L. H., Dember, L. M., Vazquez, M. A., Murray, D., DeBar, L., Staman, K. L., ... Sugarman, J. (2019). Addressing guideline and policy changes during pragmatic clinical trials. Clinical trials (London, England), 16(4), 431-437. https://doi.org/10.1177/1740774519845682

Addressing guideline and policy changes during pragmatic clinical trials. / Curtis, Lesley H.; Dember, Laura M.; Vazquez, Miguel A; Murray, David; DeBar, Lynn; Staman, Karen L.; Septimus, Edward; Mor, Vincent; Volandes, Angelo; Wells, Barbara L.; Huang, Susan S.; Green, Beverly B.; Coronado, Gloria; Meyers, Catherine M.; Tuzzio, Leah; Hernandez, Adrian F.; Sugarman, Jeremy.

In: Clinical trials (London, England), Vol. 16, No. 4, 01.08.2019, p. 431-437.

Research output: Contribution to journalArticle

Curtis, LH, Dember, LM, Vazquez, MA, Murray, D, DeBar, L, Staman, KL, Septimus, E, Mor, V, Volandes, A, Wells, BL, Huang, SS, Green, BB, Coronado, G, Meyers, CM, Tuzzio, L, Hernandez, AF & Sugarman, J 2019, 'Addressing guideline and policy changes during pragmatic clinical trials', Clinical trials (London, England), vol. 16, no. 4, pp. 431-437. https://doi.org/10.1177/1740774519845682
Curtis, Lesley H. ; Dember, Laura M. ; Vazquez, Miguel A ; Murray, David ; DeBar, Lynn ; Staman, Karen L. ; Septimus, Edward ; Mor, Vincent ; Volandes, Angelo ; Wells, Barbara L. ; Huang, Susan S. ; Green, Beverly B. ; Coronado, Gloria ; Meyers, Catherine M. ; Tuzzio, Leah ; Hernandez, Adrian F. ; Sugarman, Jeremy. / Addressing guideline and policy changes during pragmatic clinical trials. In: Clinical trials (London, England). 2019 ; Vol. 16, No. 4. pp. 431-437.
@article{604698ef698b4f9689a7036fd6b3c477,
title = "Addressing guideline and policy changes during pragmatic clinical trials",
abstract = "While conducting a set of large-scale multi-site pragmatic clinical trials involving high-impact public health issues such as end-stage renal disease, opioid use, and colorectal cancer, there were substantial changes to both policies and guidelines relevant to the trials. These external changes gave rise to unexpected challenges for the trials, including decisions regarding how to respond to new clinical practice guidelines, increased difficulty in implementing trial interventions, achieving separation between treatment groups, and differential responses across sites. In this article, we describe these challenges and the approaches used to address them. When deliberating appropriate action in the face of external changes during a pragmatic clinical trial, we recommend considering the well-being of the participants, clinical equipoise, and the strength and quality of the evidence associated with the change; involving those charged with data and safety monitoring; and where possible, planning for potential external changes as the trial is being designed. Any solution must balance the primary obligation to protect the well-being of participants with the secondary obligation to protect the integrity of the trial in order to gain meaningful answers to important public health questions.",
keywords = "guideline changes, Pragmatic clinical trials, pragmatic research, public health",
author = "Curtis, {Lesley H.} and Dember, {Laura M.} and Vazquez, {Miguel A} and David Murray and Lynn DeBar and Staman, {Karen L.} and Edward Septimus and Vincent Mor and Angelo Volandes and Wells, {Barbara L.} and Huang, {Susan S.} and Green, {Beverly B.} and Gloria Coronado and Meyers, {Catherine M.} and Leah Tuzzio and Hernandez, {Adrian F.} and Jeremy Sugarman",
year = "2019",
month = "8",
day = "1",
doi = "10.1177/1740774519845682",
language = "English (US)",
volume = "16",
pages = "431--437",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Addressing guideline and policy changes during pragmatic clinical trials

AU - Curtis, Lesley H.

AU - Dember, Laura M.

AU - Vazquez, Miguel A

AU - Murray, David

AU - DeBar, Lynn

AU - Staman, Karen L.

AU - Septimus, Edward

AU - Mor, Vincent

AU - Volandes, Angelo

AU - Wells, Barbara L.

AU - Huang, Susan S.

AU - Green, Beverly B.

AU - Coronado, Gloria

AU - Meyers, Catherine M.

AU - Tuzzio, Leah

AU - Hernandez, Adrian F.

AU - Sugarman, Jeremy

PY - 2019/8/1

Y1 - 2019/8/1

N2 - While conducting a set of large-scale multi-site pragmatic clinical trials involving high-impact public health issues such as end-stage renal disease, opioid use, and colorectal cancer, there were substantial changes to both policies and guidelines relevant to the trials. These external changes gave rise to unexpected challenges for the trials, including decisions regarding how to respond to new clinical practice guidelines, increased difficulty in implementing trial interventions, achieving separation between treatment groups, and differential responses across sites. In this article, we describe these challenges and the approaches used to address them. When deliberating appropriate action in the face of external changes during a pragmatic clinical trial, we recommend considering the well-being of the participants, clinical equipoise, and the strength and quality of the evidence associated with the change; involving those charged with data and safety monitoring; and where possible, planning for potential external changes as the trial is being designed. Any solution must balance the primary obligation to protect the well-being of participants with the secondary obligation to protect the integrity of the trial in order to gain meaningful answers to important public health questions.

AB - While conducting a set of large-scale multi-site pragmatic clinical trials involving high-impact public health issues such as end-stage renal disease, opioid use, and colorectal cancer, there were substantial changes to both policies and guidelines relevant to the trials. These external changes gave rise to unexpected challenges for the trials, including decisions regarding how to respond to new clinical practice guidelines, increased difficulty in implementing trial interventions, achieving separation between treatment groups, and differential responses across sites. In this article, we describe these challenges and the approaches used to address them. When deliberating appropriate action in the face of external changes during a pragmatic clinical trial, we recommend considering the well-being of the participants, clinical equipoise, and the strength and quality of the evidence associated with the change; involving those charged with data and safety monitoring; and where possible, planning for potential external changes as the trial is being designed. Any solution must balance the primary obligation to protect the well-being of participants with the secondary obligation to protect the integrity of the trial in order to gain meaningful answers to important public health questions.

KW - guideline changes

KW - Pragmatic clinical trials

KW - pragmatic research

KW - public health

UR - http://www.scopus.com/inward/record.url?scp=85070727344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070727344&partnerID=8YFLogxK

U2 - 10.1177/1740774519845682

DO - 10.1177/1740774519845682

M3 - Article

VL - 16

SP - 431

EP - 437

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 4

ER -